Compare HFWA & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | BBNX |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 997.9M |
| IPO Year | 1997 | 2025 |
| Metric | HFWA | BBNX |
|---|---|---|
| Price | $27.79 | $18.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $32.80 | $23.28 |
| AVG Volume (30 Days) | 349.6K | ★ 1.3M |
| Earning Date | 10-22-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | 58.06 | ★ 78.95 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | $36.38 | $25.74 |
| Revenue Next Year | $7.74 | $44.51 |
| P/E Ratio | $31.07 | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $21.32 | $8.80 |
| 52 Week High | $31.25 | $32.71 |
| Indicator | HFWA | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 45.45 |
| Support Level | $27.43 | $15.76 |
| Resistance Level | $28.13 | $20.48 |
| Average True Range (ATR) | 0.49 | 1.65 |
| MACD | -0.04 | -0.33 |
| Stochastic Oscillator | 11.99 | 42.11 |
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.